Natrilix SR

Active Ingredient & Mechanism of Action

• Active Ingredient: Indapamide (1.5 mg).
• Mechanism: Indapamide acts primarily on the cortical dilution segment of the distal convoluted tubules in the kidneys:
  1. Electrolyte Clearance: It inhibits the reabsorption of sodium and chloride, increasing their excretion alongside mild fluid elimination. Unlike conventional loop or high-ceiling diuretics, indapamide produces only a modest diuretic effect at therapeutic doses.
  2. Direct Vasodilation: Over long-term use, its primary blood pressure-lowering effect is mediated by improving arterial compliance and reducing total peripheral vascular resistance.
  3. Target End-Organ Protection: Helps reduce left ventricular hypertrophy associated with chronic hypertension.

Dosage Forms & Available Strengths

• Natrilix SR 1.5 mg Prolonged-Release Tablets: White, round, film-coated matrix tablets designed for sustained delivery over 24 hours.

Clinical Indications

• Essential Hypertension: Management of primary high blood pressure in adult patients. It can be used as monotherapy or combined with other antihypertensive agents (e.g., ACE inhibitors, calcium channel blockers, or beta-blockers).

Key Pharmacokinetics

• Absorption: Completely absorbed from the gastrointestinal tract following oral administration.
• Peak Plasma Levels ($C_{max}$): Reached approximately 12 hours post-ingestion due to the slow-release matrix system.
• Half-Life & Elimination: Elimination half-life ranges from 14 to 24 hours (mean ~18 hours). Steady state is achieved within 7 days of daily administration. Approximately 70% is eliminated via the kidneys and 22% via feces, primarily as inactive metabolites.

Administration Guidelines

• Usage: Administered orally once daily (1 tablet every 24 hours), preferably in the morning.
• Method: Must be swallowed whole with water. Do not chew, break, or crush the tablet, as damaging the film matrix destroys its sustained-release properties.
• Dose Escalation Note: Increasing the dose beyond 1.5 mg daily does not significantly increase antihypertensive efficacy but increases the risk of electrolyte imbalances.

Safety Profile & Considerations

• Common Side Effects: Headache, fatigue, dizziness, muscle cramps, skin rashes, gastrointestinal discomfort, and low blood potassium levels (hypokalemia).
• Metabolic & Neutral Profile: Unlike standard thiazide diuretics, indapamide at the 1.5 mg sustained-release dose does not significantly impair carbohydrate metabolism (glucose levels) or lipid profiles (triglycerides, HDL, LDL).
• Contraindications:
  • Severe renal failure (creatinine clearance below 30 mL/min).
  • Severe hepatic impairment or hepatic encephalopathy.
  • Pre-existing severe hypokalemia.
  • Known hypersensitivity to indapamide, other sulfonamide-derived drugs, or formulation excipients (contains lactose monohydrate).
• Key Drug Interactions:
  • Lithium: Concomitant use decreases renal lithium clearance, leading to elevated serum lithium levels and heightened toxicity risks.
  • Torsades de Pointes–Inducing Drugs (e.g., certain antiarrhythmics): Hypokalemia induced by diuretics increases the risk of serious ventricular arrhythmias.
  • NSAIDs: May reduce the blood pressure-lowering effect of indapamide and increase the risk of acute renal function decline.

Note: Natrilix SR is a prescription-only drug. Treatment, patient monitoring, and electrolyte testing should be managed under the supervision of a licensed healthcare professional.